PCVX,ATHA Stock Price and Quote

Dollar change -0.21
Percentage change -0.18	%

Held by: IWM VTI VB VXF IWO XBI VBK IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-4.76	Insider Own	4.23%	Shs Outstand	121.80M	Perf Week	2.63%
Market Cap	14.19B	Forward P/E	-	EPS next Y	-4.96	Insider Trans	-4.37%	Shs Float	116.65M	Perf Month	47.46%
Income	-497.19M	PEG	-	EPS next Q	-1.12	Inst Own	97.98%	Short Float	8.83%	Perf Quarter	61.30%
Sales	0.00M	P/S	-	EPS this Y	-4.70%	Inst Trans	5.42%	Short Ratio	10.02	Perf Half Y	72.40%
Book/sh	17.96	P/B	6.49	EPS next Y	-14.37%	ROA	-27.70%	Short Interest	10.30M	Perf Year	129.45%
Cash/sh	11.93	P/C	9.77	EPS next 5Y	-	ROE	-29.08%	52W Range	44.20 - 119.50	Perf YTD	85.57%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-46.98%	ROI	-24.80%	52W High	-2.48%	Beta	0.91
Dividend TTM	-	Quick Ratio	17.88	Sales past 5Y	0.00%	Gross Margin	-	52W Low	163.67%	ATR (14)	4.74
Dividend Ex-Date	-	Current Ratio	17.88	EPS Y/Y TTM	-41.53%	Oper. Margin	0.00%	RSI (14)	78.04	Volatility	3.19% 3.83%
Employees	254	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	145.00
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-57.50%	Payout	-	Rel Volume	0.59	Prev Close	116.75
Sales Surprise	-	EPS Surprise	-12.75%	Sales Q/Q	-	Earnings	Aug 06 AMC	Avg Volume	1.03M	Price	116.54
SMA20	18.78%	SMA50	33.87%	SMA200	60.93%	Trades		Volume	606,434	Change	-0.18%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-07-23	Initiated	Mizuho	Buy	$69
Apr-18-23	Initiated	TD Cowen	Outperform
Jan-03-23	Reiterated	Needham	Buy	$52 → $58
Dec-15-22	Initiated	Guggenheim	Buy	$66
Nov-17-22	Initiated	BTIG Research	Buy	$69
Dec-29-21	Resumed	Jefferies	Buy	$50
Jun-24-21	Resumed	Jefferies	Buy	$50
Jul-07-20	Initiated	Needham	Buy	$40
Jul-07-20	Initiated	Cantor Fitzgerald	Overweight	$55
Jul-07-20	Initiated	BofA Securities	Buy	$37

Sep-14-24 07:47PM	Vaxcyte, Inc. (PCVX): Among Hedge Funds Top Biotech Stock Picks (Insider Monkey)
Sep-11-24 04:05PM	Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-06-24 04:05PM	Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
07:00AM	Obesity drug startup raises $67M; Vors shielded transplant shows promise (BioPharma Dive)
Sep-04-24 11:58PM	Vaxcyte Announces Pricing of $1.3 Billion Public Offering (GlobeNewswire)
06:06PM	Loading…
Sep-03-24 06:06PM	Vaccine Maker Raising $1 Billion Leads Post-Holiday Share Sales (Bloomberg) +36.39%
04:09PM	Vaxcyte Catapults As It Looks To Take On Pfizer, Merck In A Massive Market (Investor's Business Daily)
04:01PM	Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
01:22PM	Heard on the Street: Pfizer Better Watch Out for This Biotech (The Wall Street Journal)
11:43AM	Biotech Startup Vaxcyte Is a Threat to Pfizer and Merck. A Vaccine Candidate Is Why. (Barrons.com)
10:48AM	Look Out, Pfizer and Merck. Vaxcyte Posts Strong Pneumococcal Vaccine Data. (Barrons.com)
09:40AM	Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher (Benzinga)
09:07AM	Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market (Investor's Business Daily)
08:10AM	Vaxcytes best-case data for pneumococcal vaccine boost shares (BioPharma Dive)
07:07AM	Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older (GlobeNewswire)
06:40PM	Loading…
Sep-02-24 06:40PM	Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older (GlobeNewswire)
Aug-06-24 04:05PM	Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-05-24 07:02PM	Insider Sale: COO Jim Wassil Sells 3,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com)
Jul-31-24 09:55AM	Wall Street Analysts See a 25.16% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High? (Zacks)
Jul-29-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Vaxcyte, Inc. (PCVX) is a Great Choice (Zacks)
Jul-02-24 07:01PM	Insider Sale: COO Jim Wassil Sells 3,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com)
08:30AM	Vaxcyte Appoints John Furey to Board of Directors (GlobeNewswire)
May-10-24 12:32PM	Vaxcyte Inc (PCVX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Overview (GuruFocus.com)
May-08-24 10:55PM	PCVX Stock Earnings: Vaxcyte Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-04-24 02:31AM	Insider Sale at Vaxcyte Inc: COO Jim Wassil Sells 3,000 Shares (GuruFocus.com)
Apr-22-24 04:46PM	Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing (MT Newswires)
Apr-02-24 04:05PM	Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-26-24 09:02PM	Sutro Biopharma Inc (STRO) Earnings: A Mixed Bag Amidst Strategic Advances (GuruFocus.com)
Mar-20-24 07:01PM	Insider Sell: Vaxcyte Inc (PCVX) CFO Andrew Guggenhime Sells 8,000 Shares (GuruFocus.com)
08:50AM	Loading…
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-04-24 08:30AM	Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants (GlobeNewswire)
Feb-28-24 12:08PM	Q4 2023 Vaxcyte Inc Earnings Call (Thomson Reuters StreetEvents) -7.33%
12:00PM	Vaxcyte, Inc. (PCVX) Is Up 2.14% in One Week: What You Should Know (Zacks)
09:57AM	Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 04:01PM	Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-26-24 08:32AM	Why Vaxcyte (PCVX) Might Surprise This Earnings Season (Zacks)
Feb-25-24 11:05AM	5 Best Russell 2000 Stocks To Buy According To Hedge Funds (Insider Monkey)
Feb-22-24 11:28PM	Insider Sell: Vaxcyte Inc CFO Andrew Guggenhime Disposes of 8,000 Shares (GuruFocus.com)
Feb-15-24 04:05PM	Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 (GlobeNewswire)
Feb-02-24 11:12PM	Director Heath Lukatch Sells 5,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com)
06:39PM	Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Feb-01-24 11:02PM	Director Heath Lukatch Sells 4,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com) +5.75%
04:05PM	Vaxcyte to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-30-24 11:37PM	Vaxcyte Announces Pricing of $750 Million Public Offering (GlobeNewswire) +6.04%
04:01PM	Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jan-29-24 08:30AM	Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older (GlobeNewswire) +6.52%
Jan-19-24 08:28PM	Insider Sell: Vaxcyte Inc CFO Andrew Guggenhime Sells 8,000 Shares (GuruFocus.com)
Jan-16-24 04:01PM	Vaxcyte Appoints Whitney Jones as Chief People Officer (GlobeNewswire)
Jan-04-24 04:01PM	Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise (GlobeNewswire) -7.07%
Dec-21-23 05:01PM	Insider Sell: Vaxcyte Inc CFO Andrew Guggenhime Disposes of 8,000 Shares (GuruFocus.com)
Dec-04-23 06:35PM	VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate (GlobeNewswire)
Nov-28-23 08:30AM	Vaxcyte Appoints Jacks Lee to Board of Directors (GlobeNewswire)
Nov-27-23 04:00PM	Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates (GlobeNewswire)
Nov-23-23 11:04AM	Insider Sell Alert: Vaxcyte Inc's President and CFO Andrew Guggenhime Sells 8,000 Shares (GuruFocus.com)
Nov-09-23 08:30AM	Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults (GlobeNewswire) -5.06%
Nov-06-23 05:19PM	Vaxcyte Inc (PCVX) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
04:03PM	Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-23 11:54PM	Insider Sell: COO Jim Wassil Sells 3,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com) +6.17%
Oct-31-23 04:05PM	Vaxcyte to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-20-23 09:55PM	Insider Sell: Andrew Guggenhime Sells 8,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com)
Oct-19-23 08:30AM	Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults (GlobeNewswire)
Oct-16-23 08:00AM	Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs) (GlobeNewswire)
Oct-04-23 11:00PM	Insider Sell: Vaxcyte Inc's COO Jim Wassil Sells 3,000 Shares (GuruFocus.com)
Sep-19-23 04:05PM	Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Sep-11-23 08:21AM	Codexis (CDXS) Transfers Leasing Rights to Vaxcyte, Stock Up (Zacks)
Sep-08-23 04:44PM	Peninsula biotech grabs more space as it plans to take 2nd pneumonia vaccine into clinic (American City Business Journals)
Aug-08-23 04:03PM	Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-11-23 08:30AM	Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants (GlobeNewswire)
Jul-01-23 09:05AM	Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jun-13-23 09:30AM	5 Biotech Stocks to Buy as Industry Prospects for 2H23 Look Good (Zacks)
Jun-01-23 04:05PM	Vaxcyte to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-29-23 09:55AM	Wall Street Analysts Think Vaxcyte, Inc. (PCVX) Could Surge 33.33%: Read This Before Placing a Bet (Zacks)
May-12-23 09:55AM	Wall Street Analysts Believe Vaxcyte, Inc. (PCVX) Could Rally 26.15%: Here's is How to Trade (Zacks)
May-08-23 04:03PM	Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-03-23 04:05PM	Vaxcyte to Present at the BofA Securities 2023 Health Care Conference (GlobeNewswire) +5.21%
Apr-21-23 05:25PM	Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Apr-19-23 11:36AM	Biotech Stock Roundup: MDGL, PCVX Up on Study Data, MRNA Provides Updates (Zacks)
12:26AM	Vaxcyte Announces Pricing of $500 Million Public Offering (GlobeNewswire)
Apr-18-23 12:56PM	Vaxcyte (PCVX) Up on Pneumococcal Conjugate Vaccine Data (Zacks)
Apr-17-23 04:05PM	Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +16.00%
06:30AM	Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies (GlobeNewswire)
Apr-16-23 05:00PM	Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies (GlobeNewswire)
Mar-30-23 08:30AM	Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants (GlobeNewswire)
Mar-12-23 11:55PM	Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Feb-27-23 04:01PM	Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Feb-21-23 08:30AM	Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants (GlobeNewswire)
Feb-16-23 04:05PM	Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023 (GlobeNewswire)
Feb-07-23 04:05PM	Vaxcyte to Present at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-22-23 07:39AM	We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely (Simply Wall St.)
Jan-05-23 08:30AM	Vaxcytes VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults (GlobeNewswire)
Jan-03-23 12:34PM	This Pneumococcal Vaccine Player Is The Top Pick For 2023 For This Analyst (Benzinga)
Dec-20-22 04:05PM	Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract (GlobeNewswire)
Dec-11-22 07:21PM	TipRanks Perfect 10 List: These 3 Top-Rated Stocks Could Shine in 2023 (TipRanks)
Nov-07-22 04:10PM	Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-22 08:30AM	Vaxcyte to Present at Upcoming Investor Conferences (GlobeNewswire) +5.41%
Oct-31-22 02:58PM	Drugmakers Fight Over Lucrative Pneumonia Vaccines (The Wall Street Journal)
Oct-30-22 09:13AM	Vaxcyte, Inc.'s (NASDAQ:PCVX) large institutional owners must be happy as stock continues to impress, up 111% over the past week (Simply Wall St.)
Oct-29-22 11:03AM	Why Shares of Vaxcyte Rose 110.7% This Week (Motley Fool)
Oct-28-22 04:01PM	Vaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire) +5.40%

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Loxam Teri	Director	Sep 17 '24	Option Exercise	22.70	6,250	141,875	13,425	Sep 18 04:24 PM
Loxam Teri	Director	Sep 17 '24	Sale	116.28	6,250	726,731	7,175	Sep 18 04:24 PM
Wassil Jim	CHIEF OPERATING OFFICER	Sep 16 '24	Option Exercise	2.42	10,000	24,200	211,958	Sep 18 04:23 PM
Wassil Jim	CHIEF OPERATING OFFICER	Sep 16 '24	Sale	115.96	10,000	1,159,635	200,646	Sep 18 04:23 PM
GUGGENHIME ANDREW	Officer	Sep 18 '24	Proposed Sale	116.75	8,000	934,000		Sep 18 04:11 PM
Loxam Teri	Director	Sep 17 '24	Proposed Sale	113.93	6,250	712,062		Sep 17 04:11 PM
Wassil Jim	Officer	Sep 16 '24	Proposed Sale	115.90	10,000	1,159,000		Sep 16 04:17 PM
Wassil Jim	CHIEF OPERATING OFFICER	Sep 03 '24	Option Exercise	2.42	10,000	24,200	217,503	Sep 05 05:19 PM
Wassil Jim	CHIEF OPERATING OFFICER	Sep 03 '24	Sale	111.93	10,000	1,119,252	207,503	Sep 05 05:19 PM
Cowan Elvia	SVP, FINANCE	Sep 03 '24	Option Exercise	25.92	5,000	129,600	17,723	Sep 05 05:15 PM
Cowan Elvia	SVP, FINANCE	Sep 03 '24	Sale	107.67	5,000	538,350	12,723	Sep 05 05:15 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Sep 03 '24	Option Exercise	21.41	1,667	35,690	32,493	Sep 05 05:13 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Sep 03 '24	Sale	112.11	1,667	186,880	30,826	Sep 05 05:13 PM
Cowan Elvia	Officer	Sep 03 '24	Proposed Sale	107.67	5,000	538,350		Sep 03 04:08 PM
Wassil Jim	Officer	Sep 03 '24	Proposed Sale	107.67	10,000	1,076,700		Sep 03 04:07 PM
Eydelman Mikhail	Officer	Sep 03 '24	Proposed Sale	107.67	1,667	179,485		Sep 03 04:04 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Aug 23 '24	Option Exercise	2.03	15,000	30,450	493,888	Aug 26 04:58 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Aug 23 '24	Sale	78.98	15,000	1,184,767	478,888	Aug 26 04:58 PM
PICKERING GRANT	Officer	Aug 23 '24	Proposed Sale	78.89	15,000	1,183,350		Aug 23 04:03 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Aug 19 '24	Option Exercise	5.35	8,000	42,800	104,720	Aug 20 04:49 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Aug 19 '24	Sale	78.58	8,000	628,650	96,720	Aug 20 04:49 PM
GUGGENHIME ANDREW	Officer	Aug 19 '24	Proposed Sale	78.91	8,000	631,280		Aug 19 04:05 PM
Wassil Jim	CHIEF OPERATING OFFICER	Aug 01 '24	Sale	78.84	3,000	236,527	207,503	Aug 05 04:10 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Aug 01 '24	Sale	78.79	2,616	206,122	142,130	Aug 05 04:08 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Aug 01 '24	Option Exercise	21.41	1,667	35,690	32,493	Aug 05 04:06 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Aug 01 '24	Sale	78.85	1,667	131,449	30,826	Aug 05 04:06 PM
PICKERING GRANT	Officer	Aug 01 '24	Proposed Sale	78.80	2,616	206,141		Aug 01 04:04 PM
Wassil Jim	Officer	Aug 01 '24	Proposed Sale	78.80	3,000	236,400		Aug 01 04:02 PM
Eydelman Mikhail	Officer	Aug 01 '24	Proposed Sale	78.80	1,667	131,360		Aug 01 04:01 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jul 23 '24	Option Exercise	2.03	15,000	30,450	493,888	Jul 24 05:44 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jul 23 '24	Sale	84.26	15,000	1,263,912	478,888	Jul 24 05:44 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jul 18 '24	Option Exercise	5.35	8,000	42,800	104,720	Jul 22 04:03 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jul 18 '24	Sale	81.17	8,000	649,325	96,720	Jul 22 04:03 PM
Cowan Elvia	SVP, FINANCE	Jul 16 '24	Option Exercise	25.92	5,000	129,600	17,723	Jul 17 04:03 PM
Cowan Elvia	SVP, FINANCE	Jul 16 '24	Sale	85.00	5,000	425,000	12,723	Jul 17 04:03 PM
Cowan Elvia	SVP, FINANCE	Jul 08 '24	Option Exercise	25.92	5,000	129,600	17,723	Jul 09 05:15 PM
Cowan Elvia	SVP, FINANCE	Jul 08 '24	Sale	80.00	5,000	400,000	12,723	Jul 09 05:15 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Jul 01 '24	Option Exercise	21.41	1,667	35,690	32,493	Jul 02 04:17 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Jul 01 '24	Sale	76.37	1,667	127,304	30,826	Jul 02 04:17 PM
Wassil Jim	CHIEF OPERATING OFFICER	Jul 01 '24	Sale	76.34	3,000	229,013	210,503	Jul 02 04:16 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jul 01 '24	Sale	76.33	2,616	199,690	143,438	Jul 02 04:12 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jun 24 '24	Option Exercise	2.03	15,000	30,450	493,888	Jun 25 04:43 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jun 24 '24	Sale	75.64	15,000	1,134,579	478,888	Jun 25 04:43 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jun 18 '24	Option Exercise	5.35	8,000	42,800	104,720	Jun 20 08:30 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jun 18 '24	Sale	71.92	8,000	575,375	96,720	Jun 20 08:30 PM
Gilbert Halley E	Director	Jun 03 '24	Option Exercise	5.35	18,200	97,370	23,825	Jun 05 04:59 PM
Gilbert Halley E	Director	Jun 03 '24	Sale	73.00	18,200	1,328,600	5,625	Jun 05 04:59 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Jun 03 '24	Option Exercise	21.41	1,667	35,690	32,828	Jun 05 04:58 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Jun 03 '24	Sale	72.06	1,667	120,127	31,161	Jun 05 04:58 PM
Wassil Jim	CHIEF OPERATING OFFICER	Jun 03 '24	Sale	71.99	3,000	215,961	213,503	Jun 05 04:57 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jun 03 '24	Sale	72.06	2,616	188,512	144,746	Jun 05 04:56 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	May 23 '24	Option Exercise	2.03	15,000	30,450	492,847	May 28 04:22 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	May 23 '24	Sale	69.43	15,000	1,041,408	477,847	May 28 04:22 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	May 20 '24	Option Exercise	5.35	8,000	42,800	103,679	May 22 05:03 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	May 20 '24	Sale	74.99	8,000	599,909	95,679	May 22 05:03 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	May 01 '24	Option Exercise	21.41	1,667	35,690	32,264	May 03 04:20 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	May 01 '24	Sale	61.74	1,667	102,921	30,597	May 03 04:20 PM
Wassil Jim	CHIEF OPERATING OFFICER	May 01 '24	Sale	61.65	3,000	184,942	215,462	May 03 04:19 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	May 01 '24	Sale	61.70	2,616	161,419	146,054	May 03 04:18 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Apr 23 '24	Option Exercise	1.79	15,000	26,850	492,847	Apr 25 04:52 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Apr 23 '24	Sale	61.92	15,000	928,845	477,847	Apr 25 04:52 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Apr 18 '24	Option Exercise	5.35	8,000	42,800	103,679	Apr 22 04:42 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Apr 18 '24	Sale	61.27	8,000	490,199	95,679	Apr 22 04:42 PM
Wassil Jim	CHIEF OPERATING OFFICER	Apr 17 '24	Option Exercise	5.35	3,551	18,998	221,840	Apr 19 04:31 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Apr 01 '24	Option Exercise	21.41	1,667	35,690	32,264	Apr 03 04:22 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Apr 01 '24	Sale	66.73	1,667	111,234	30,597	Apr 03 04:22 PM
Wassil Jim	CHIEF OPERATING OFFICER	Apr 01 '24	Sale	66.69	3,000	200,066	218,289	Apr 03 04:22 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Apr 01 '24	Sale	66.71	2,616	174,502	147,362	Apr 03 04:21 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Mar 25 '24	Option Exercise	1.79	15,000	26,850	492,847	Mar 27 04:44 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Mar 25 '24	Sale	66.93	15,000	1,003,978	477,847	Mar 27 04:44 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Mar 18 '24	Option Exercise	5.35	8,000	42,800	103,679	Mar 20 04:29 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Mar 18 '24	Sale	69.02	8,000	552,144	95,679	Mar 20 04:29 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Mar 11 '24	Option Exercise	2.03	65,000	131,950	477,847	Mar 13 04:22 PM
Wassil Jim	CHIEF OPERATING OFFICER	Mar 01 '24	Sale	73.71	3,000	221,134	220,852	Mar 04 09:23 PM
Cowan Elvia	SVP, FINANCE	Mar 01 '24	Option Exercise	25.92	11,000	285,120	24,158	Mar 04 09:22 PM
Cowan Elvia	SVP, FINANCE	Mar 01 '24	Sale	74.08	11,678	865,070	12,480	Mar 04 09:22 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Mar 01 '24	Option Exercise	21.41	1,667	35,690	32,877	Mar 04 09:21 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Mar 01 '24	Sale	73.73	1,667	122,907	31,210	Mar 04 09:21 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Mar 01 '24	Sale	73.70	2,616	192,799	148,670	Mar 04 09:19 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Feb 26 '24	Option Exercise	1.79	30,000	53,700	405,814	Feb 27 04:17 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Feb 23 '24	Option Exercise	1.79	15,000	26,850	390,814	Feb 27 04:17 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Feb 26 '24	Sale	79.03	30,000	2,370,900	375,814	Feb 27 04:17 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Feb 23 '24	Sale	76.21	15,000	1,143,206	375,814	Feb 27 04:17 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Feb 20 '24	Option Exercise	5.35	8,000	42,800	87,474	Feb 22 04:30 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Feb 20 '24	Sale	74.53	8,000	596,232	79,474	Feb 22 04:30 PM
Wassil Jim	CHIEF OPERATING OFFICER	Feb 15 '24	Option Exercise	2.42	27,917	67,559	203,852	Feb 20 04:22 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Feb 01 '24	Option Exercise	21.41	1,667	35,690	22,377	Feb 05 05:39 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Feb 01 '24	Sale	73.87	1,667	123,144	20,710	Feb 05 05:39 PM
Wassil Jim	CHIEF OPERATING OFFICER	Feb 01 '24	Option Exercise	2.42	3,000	7,260	178,935	Feb 05 05:37 PM
Wassil Jim	CHIEF OPERATING OFFICER	Feb 01 '24	Sale	73.88	3,000	221,626	175,935	Feb 05 05:37 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Feb 01 '24	Sale	73.91	2,616	193,353	149,978	Feb 05 05:33 PM
Lukatch Heath	Director	Jan 31 '24	Option Exercise	16.00	5,000	80,000	10,625	Feb 02 04:40 PM
Lukatch Heath	Director	Jan 31 '24	Sale	71.50	5,000	357,500	5,625	Feb 02 04:40 PM
Lukatch Heath	Director	Jan 29 '24	Option Exercise	16.00	4,000	64,000	9,625	Jan 31 04:12 PM
Lukatch Heath	Director	Jan 29 '24	Sale	67.50	4,000	270,000	5,625	Jan 31 04:12 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jan 29 '24	Option Exercise	1.79	30,000	53,700	405,814	Jan 31 04:11 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jan 29 '24	Sale	66.03	30,000	1,980,900	375,814	Jan 31 04:11 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jan 23 '24	Option Exercise	1.44	15,000	21,600	390,814	Jan 25 05:50 PM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Jan 23 '24	Sale	63.92	15,000	958,783	375,814	Jan 25 05:50 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jan 18 '24	Option Exercise	5.35	8,000	42,800	87,474	Jan 19 04:17 PM

PCVX

Vaxcyte Inc

ATHA

Athira Pharma Inc

Upgrade your FINVIZ experience